A Phase 3 interventional study of Adalimumab in Intestinal Behçet's Disease, sponsored by AbbVie (prior sponsor, Abbott). Completed at 12 sites in Japan. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2014-07-25.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate efficacy, safety and pharmacokinetics of adalimumab subcutaneous (sc) for Japanese subjects with intestinal Behçet's disease who are refractory to conventional therapies.
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adalimumab 160 mg at Week 0, 80 mg at Week 2 and 40 mg every other week (eow) starting at Week 4 to Week 50, subcutaneous injection. After Week 52, participants could continue the treatment with 40 mg eow until the day before approval of adalimumab for intestinal Behçet's disease in Japan.
Biological: Adalimumab
Also known as: ABT-D2E7, Humira
Number of Participants With Marked Improvement at Week 24
Marked improvement is defined as the combination of both global assessment of gastrointestinal (GI) symptoms and endoscopic improvement grades of ≤1. Global assessment of GI symptoms is a participant-assessed, investigator-confirmed grading of global symptoms from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Endoscopic improvement was assessed in 4 grades compared to the screening endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion).
Time frame: 24 weeks
Number of Participants With Marked Improvement at Week 52
Marked improvement is defined as the combination of both global assessment of gastrointestinal (GI) symptoms and endoscopic improvement grades of ≤1. Global assessment of GI symptoms is a participant-assessed, investigator-confirmed grading of global symptoms from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Endoscopic improvement was assessed in 4 grades compared to the screening endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion).
Time frame: 52 weeks
Number of Participants With Complete Remission at Week 24 and Week 52
Complete remission was defined as both endoscopic improvement and global assessment of gastrointestinal symptoms grades of 0. Endoscopic improvement was assessed in 4 grades compared to the screening (baseline) endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion). Global assessment of gastrointestinal symptoms is a participant-assessed, investigator-confirmed grading of global symptoms from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life.
Time frame: 24 weeks, 52 weeks
Number of Participants With a Global Assessment of Gastrointestinal Symptoms Grade 0 or ≤1 and Improvement of ≥1 Grade at Week 24 and Week 52
Study participants completed a global assessment of their gastrointestinal symptoms (Behçet's disease symptoms other than gastrointestinal symptoms were excluded) during 2 weeks before assessment visit on a 5-grade scale. The investigator confirmed this assessment via interview with participants. Assessment is graded from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Global assessment of grade 0 or ≤1 and improvement of ≥1 (from baseline) is presented.
Time frame: 24 weeks, 52 weeks
Number of Participants With Endoscopic Improvement Grades 0, ≤1 and ≤2 at Week 24 and Week 52
Endoscopic improvement was assessed in 4 grades compared to the screening (baseline) endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion).
Time frame: 24 weeks, 52 weeks
Number of Participants With Abdominal Pain, Diarrhea and Other Gastrointestinal (GI) Symptoms Grade ≤1 and Improvement of ≥1 Grade at Week 24 and Week 52
Participants assessed their abdominal pain, diarrhea and other gastrointestinal symptoms (abdominal discomfort, abdominal fullness, etc) during 2 weeks before assessment visit in 5 grades. Investigator confirmed the assessment through interview with participants. Assessment is graded from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Improvement of ≥1 grade from baseline is also presented.
Time frame: 24 weeks, 52 weeks
Number of Participants With Resolution of Behçet's Disease Symptoms (Other Than Gastrointestinal Symptoms) at Week 24 and Week 52
Investigators assessed oral aphthous (mouth ulcers), skin symptoms, eye symptoms and vulval (genital) ulcers during 4 weeks before study visit via participant interview, using the following grades. Oral aphthous: 0=None; 1=Symptom existed less than 2 weeks in recent 4 weeks; 2=Symptom existed 2 weeks or more in recent 4 weeks; 3=Symptom existed mostly in recent 4 weeks. Skin (Erythema nodosum rash): 0=None; 1=Symptom existed less than 2 weeks in recent 4 weeks; 2=Symptom existed 2 weeks or more in recent 4 weeks; 3=Symptom existed mostly in recent 4 weeks. Eye (Uveitis): 0=None; 1=one eye crisis in recent 4 weeks; 2=two eye crises in recent 4 weeks; 3=three eye crises in recent 4 weeks. Vulval (genital) ulcer: 0=None; 1=Symptom existed less than 2 weeks in recent 4 weeks; 2=Symptom existed 2 weeks or more in recent 4 weeks; 3=Symptom existed mostly in recent 4 weeks. Resolution was defined as: Behçet's disease symptoms other than gastrointestinal symptoms were graded 0 (disappeared).
Time frame: 24 weeks, 52 weeks
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 24 and Week 52
Inflammatory Bowel Disease Questionnaire (IBDQ) is the standard questionnaire to assess the quality of life of patients with inflammatory bowel disease. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function and emotional status. The responses to each question within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).
Time frame: Baseline, 24 weeks, 52 weeks
Mean Change From Baseline in Short Form-36 (SF-36) Summary Scores at Week 24 and Week 52
The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain and rating of one's health. Score on the physical component ranges from 0 (poorest health) to 100 (best health). The mental component reflects vitality, social functioning, role-emotional and mental health. Score on the mental component ranges from 0 (poorest health) to 100 (best health).
Time frame: Baseline, 24 weeks, 52 weeks
Median Change From Baseline in C-Reactive Protein (CRP) at Week 24 and Week 52
C-Reactive Protein (CRP) normal range was defined as ≤0.3 mg/dL.
Time frame: Baseline, 24 weeks, 52 weeks
| Milestone | Adalimumab |
|---|---|
| Started | 20 |
| Completed 24 weeks of treatment | 18 |
| Completed 52 weeks of treatment | 17 |
| Completed | 15 |
| Not completed | 5 |
| Withdrew: Adverse event | 3 |
| Withdrew: Anti-adalimumab antibody positive | 1 |
| Withdrew: Other | 1 |
Marked improvement is defined as the combination of both global assessment of gastrointestinal (GI) symptoms and endoscopic improvement grades of ≤1. Global assessment of GI symptoms is a participant-assessed, investigator-confirmed grading of global symptoms from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Endoscopic improvement was assessed in 4 grades compared to the screening endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion).
| participants | Adalimumab |
|---|---|
| Number of Participants With Marked Improvement at Week 24 | 9 |
Marked improvement is defined as the combination of both global assessment of gastrointestinal (GI) symptoms and endoscopic improvement grades of ≤1. Global assessment of GI symptoms is a participant-assessed, investigator-confirmed grading of global symptoms from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Endoscopic improvement was assessed in 4 grades compared to the screening endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion).
| participants | Adalimumab |
|---|---|
| Number of Participants With Marked Improvement at Week 52 | 12 |
Complete remission was defined as both endoscopic improvement and global assessment of gastrointestinal symptoms grades of 0. Endoscopic improvement was assessed in 4 grades compared to the screening (baseline) endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion). Global assessment of gastrointestinal symptoms is a participant-assessed, investigator-confirmed grading of global symptoms from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life.
| participants | Adalimumab |
|---|---|
| Week 24 | 4 |
| Week 52 | 4 |
Study participants completed a global assessment of their gastrointestinal symptoms (Behçet's disease symptoms other than gastrointestinal symptoms were excluded) during 2 weeks before assessment visit on a 5-grade scale. The investigator confirmed this assessment via interview with participants. Assessment is graded from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Global assessment of grade 0 or ≤1 and improvement of ≥1 (from baseline) is presented.
| participants | Adalimumab |
|---|---|
| Week 24: Grade 0 | 9 |
| Week 24: Grade ≤1 | 13 |
| Week 24: Improvement of ≥1 Grade | 16 |
| Week 52: Grade 0 | 9 |
| Week 52: Grade ≤1 | 16 |
| Week 52: Improvement of ≥1 Grade | 18 |
Endoscopic improvement was assessed in 4 grades compared to the screening (baseline) endoscopy based on the longest diameter (none, ≥1 cm to \<2 cm, ≥2 cm to \<3 cm, ≥3 cm) of ileocecal largest open ulcer (area of mucosal defect). Grades are: 0=healing; 1=marked reduction (reduction to ≤1/4); 2=reduction (reduction to ≤1/2 - 1/4); 3=no change or worse (reduction less than 1/2 or expansion).
| participants | Adalimumab |
|---|---|
| Week 24: Grade 0 | 9 |
| Week 24: Grade ≤1 | 12 |
| Week 24: Grade ≤2 | 15 |
| Week 52: Grade 0 | 11 |
| Week 52: Grade ≤1 | 13 |
| Week 52: Grade ≤2 | 15 |
Participants assessed their abdominal pain, diarrhea and other gastrointestinal symptoms (abdominal discomfort, abdominal fullness, etc) during 2 weeks before assessment visit in 5 grades. Investigator confirmed the assessment through interview with participants. Assessment is graded from 0 to 4: 0=free of symptoms; 1=symptoms existed in past 2 weeks but did not affect participant's daily life; 2=symptoms existed in past 2 weeks and slightly affected participant's daily life; 3=symptoms existed in past 2 weeks and affected participant's daily life; 4=symptoms existed in past 2 weeks and critically affected participant's daily life. Improvement of ≥1 grade from baseline is also presented.
| participants | Adalimumab |
|---|---|
| Week 24: Abdominal Pain Grade ≤1; n=18 | 11 |
| Week 24: Diarrhea Grade ≤1; n=16 | 13 |
| Week 24: Other GI Symptom Grade ≤1; n=20 | 16 |
| Week 24:Abdominal Pain Improvement ≥1 Grade; n=18 | 14 |
| Week 24: Diarrhea Improvement ≥1 Grade; n=16 | 11 |
| Week 24:Other GI Symptom Improvement ≥1 Grade;n=20 | 18 |
| Week 52: Abdominal Pain Grade ≤1; n=18 | 14 |
| Week 52: Diarrhea Grade ≤1; n=16 | 15 |
| Week 52: Other GI Symptom Grade ≤1; n=20 | 16 |
| Week 52:Abdominal Pain Improvement ≥1 Grade; n=18 | 16 |
| Week 52: Diarrhea Improvement ≥1 Grade; n=16 | 13 |
| Week 52:Other GI Symptom Improvement ≥1 Grade;n=20 | 18 |
Investigators assessed oral aphthous (mouth ulcers), skin symptoms, eye symptoms and vulval (genital) ulcers during 4 weeks before study visit via participant interview, using the following grades. Oral aphthous: 0=None; 1=Symptom existed less than 2 weeks in recent 4 weeks; 2=Symptom existed 2 weeks or more in recent 4 weeks; 3=Symptom existed mostly in recent 4 weeks. Skin (Erythema nodosum rash): 0=None; 1=Symptom existed less than 2 weeks in recent 4 weeks; 2=Symptom existed 2 weeks or more in recent 4 weeks; 3=Symptom existed mostly in recent 4 weeks. Eye (Uveitis): 0=None; 1=one eye crisis in recent 4 weeks; 2=two eye crises in recent 4 weeks; 3=three eye crises in recent 4 weeks. Vulval (genital) ulcer: 0=None; 1=Symptom existed less than 2 weeks in recent 4 weeks; 2=Symptom existed 2 weeks or more in recent 4 weeks; 3=Symptom existed mostly in recent 4 weeks. Resolution was defined as: Behçet's disease symptoms other than gastrointestinal symptoms were graded 0 (disappeared).
| participants | Adalimumab |
|---|---|
| Week 24: Oral Aphthous; n=15 | 10 |
| Week 24: Skin (Erythema nodosum rash); n=8 | 6 |
| Week 24: Eye (Uveitis); n=0 | 0 |
| Week 24: Vulval (Genital) Ulcer; n=3 | 2 |
| Week 52: Oral Aphthous; n=15 | 10 |
| Week 52: Skin (Erythema nodosum rash); n=8 | 7 |
| Week 52: Eye (Uveitis); n=0 | 0 |
| Week 52: Vulval (Genital) Ulcer; n=3 | 2 |
Inflammatory Bowel Disease Questionnaire (IBDQ) is the standard questionnaire to assess the quality of life of patients with inflammatory bowel disease. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function and emotional status. The responses to each question within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).
| units on a scale | Adalimumab |
|---|---|
| Week 24 | 37.1 ± 40.00 |
| Week 52 | 41.2 ± 41.91 |
The Short-Form-36 (SF-36) Health Survey is a comprehensive quality of life scale. An increase in SF-36 score indicates alleviation of the disease and a decrease in score indicates aggravation of disease. The physical component reflects activity level, activity limitations, pain and rating of one's health. Score on the physical component ranges from 0 (poorest health) to 100 (best health). The mental component reflects vitality, social functioning, role-emotional and mental health. Score on the mental component ranges from 0 (poorest health) to 100 (best health).
| units on a scale | Adalimumab |
|---|---|
| Week 24: Summary Score (Physical Component) | 7.5 ± 7.18 |
| Week 24: Summary Score (Mental Component) | 8.9 ± 12.85 |
| Week 52: Summary Score (Physical Component) | 9.0 ± 8.42 |
| Week 52: Summary Score (Mental Component) | 9.0 ± 13.27 |
C-Reactive Protein (CRP) normal range was defined as ≤0.3 mg/dL.
| mg/dL | Adalimumab |
|---|---|
| Week 24 | -0.3 ± 1.27 |
| Week 52 | -0.2 ± 2.22 |
Collected over Adverse Events (AEs) were reported from the time of study drug administration up to 124 weeks + 70 days following discontinuation of study drug. Serious AEs were collected from the time the participant signed the study-specific informed consent.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab | — | 6/20 (30%) | 20/20 (100%) |
| Event | Adalimumab |
|---|---|
| AUTOIMMUNE THYROIDITISEndocrine disorders | 1/20 |
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 1/20 |
| LOWER GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 1/20 |
| SUBILEUSGastrointestinal disorders | 1/20 |
| BEHCET'S SYNDROMEImmune system disorders | 1/20 |
| ABSCESS INTESTINALInfections and infestations | 1/20 |
| APPENDICITISInfections and infestations | 1/20 |
| APPENDICITIS PERFORATEDInfections and infestations | 1/20 |
| SPONDYLITIC MYELOPATHYNervous system disorders | 1/20 |
| Event | Adalimumab |
|---|---|
| NASOPHARYNGITISInfections and infestations | 11/20 |
| HEADACHENervous system disorders | 5/20 |
| BACK PAINMusculoskeletal and connective tissue disorders | 4/20 |
| COUGHRespiratory, thoracic and mediastinal disorders | 4/20 |
| DENTAL CARIESGastrointestinal disorders | 3/20 |
| DIARRHOEAGastrointestinal disorders | 3/20 |
| BEHCET'S SYNDROMEImmune system disorders | 3/20 |
| GASTROENTERITISInfections and infestations | 3/20 |
| CONTUSIONInjury, poisoning and procedural complications | 3/20 |
| RASHSkin and subcutaneous tissue disorders | 3/20 |
| Age, Continuous(years) | Adalimumab |
|---|---|
| Mean | 42.4 ± 13.33 |
| Age, Customized(participants) | Adalimumab |
|---|---|
| <40 years | 11 |
| Between 40 and 65 years | 7 |
| >=65 years | 2 |
| Sex: Female, Male(Participants) | Adalimumab |
|---|---|
| Female | 10 |
| Male | 10 |
| Longest Diameter of Ileocecal Largest Open Ulcer(participants) | Adalimumab |
|---|---|
| >=1 cm to <2 cm | 8 |
| >=2 cm to <3 cm | 5 |
| >=3 cm | 7 |
| Global Assessment of Gastrointestinal (GI) Symptoms Grade(participants) | Adalimumab |
|---|---|
| Grade 0 | 0 |
| Grade 1 | 0 |
| Grade 2 | 0 |
| Grade 3 | 15 |
| Grade 4 | 5 |
| Assessment of Abdominal Pain (GI Symptom Component) Grade(participants) | Adalimumab |
|---|---|
| Grade 0 | 2 |
| Grade 1 | 1 |
| Grade 2 | 3 |
| Grade 3 | 10 |
| Grade 4 | 4 |
| Assessment of Diarrhea (GI Symptom Component) Grade(participants) | Adalimumab |
|---|---|
| Grade 0 | 4 |
| Grade 1 | 6 |
| Grade 2 | 0 |
| Grade 3 | 9 |
| Grade 4 | 1 |
| Assessment of Other Symptoms (GI Symptom Component) Grade(participants) | Adalimumab |
|---|---|
| Grade 0 | 0 |
| Grade 1 | 1 |
| Grade 2 | 4 |
| Grade 3 | 12 |
| Grade 4 | 3 |
4 further baseline measures are reported on the registry.
The record gives a start of Oct 2010, a primary completion of Mar 2012 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
AbbVie (prior sponsor, Abbott) →